EMS-话题@MedSci

#EMS#

32篇内容 | 818人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1985089, encodeId=e016198508933, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=远程血流动力学引导的心力衰竭管理对不同亚型肺动脉高压患者的影响：来自 MEMS-HF 研究的见解, objectType=article, longId=737813, objectId=cbe3e3781371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe3e3781371, replyNumber=0, likeNumber=51, createdTime=2022-12-13, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe3e3781371, moduleTitle=远程血流动力学引导的心力衰竭管理对不同亚型肺动脉高压患者的影响：来自 MEMS-HF 研究的见解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe3e3781371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985088, encodeId=0acf1985088f9, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=POEMS综合征：症状、病因、诊断与治疗, objectType=article, longId=736090, objectId=34ace3609024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ace3609024, replyNumber=0, likeNumber=55, createdTime=2023-07-10, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ace3609024, moduleTitle=POEMS综合征：症状、病因、诊断与治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34ace3609024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985087, encodeId=552d198508ee8, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, objectType=article, longId=727255, objectId=541de2725547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541de2725547, replyNumber=0, likeNumber=36, createdTime=2022-09-30, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541de2725547, moduleTitle=GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541de2725547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985084, encodeId=90c4198508496, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, objectType=article, longId=219450, objectId=ebb921945031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebb921945031, replyNumber=0, likeNumber=46, createdTime=2022-04-05, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebb921945031, moduleTitle=Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebb921945031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985086, encodeId=b4ac19850864e, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Molecular Systems Biology：AI助力抗击细胞因子风暴，可有效对抗新冠“夺命帮凶”, objectType=article, longId=726727, objectId=2843e2672734, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2843e2672734, replyNumber=0, likeNumber=34, createdTime=2023-01-16, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2843e2672734, moduleTitle=Molecular Systems Biology：AI助力抗击细胞因子风暴，可有效对抗新冠“夺命帮凶”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2843e2672734)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985085, encodeId=2ab91985085fb, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=NEJM:加拿大解除米非司酮REMS限制对流产安全的影响, objectType=article, longId=260124, objectId=b21126012424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b21126012424, replyNumber=0, likeNumber=47, createdTime=2022-06-27, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b21126012424, moduleTitle=NEJM:加拿大解除米非司酮REMS限制对流产安全的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b21126012424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985083, encodeId=3948198508342, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=0, createdTime=2022-04-29, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985082, encodeId=0ad8198508233, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=mSystems：人造甜味剂会促进全身炎症和脂肪肝的发展，不过有一种甜味剂例外…, objectType=article, longId=208492, objectId=521e208492bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=521e208492bb, replyNumber=0, likeNumber=49, createdTime=2021-03-26, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=521e208492bb, moduleTitle=mSystems：人造甜味剂会促进全身炎症和脂肪肝的发展，不过有一种甜味剂例外…, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=521e208492bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985080, encodeId=be9e198508006, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, objectType=article, longId=202153, objectId=31d82021531a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d82021531a, replyNumber=0, likeNumber=52, createdTime=2020-12-11, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d82021531a, moduleTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31d82021531a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985074, encodeId=18df19850e41f, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市, objectType=article, longId=189172, objectId=81241891e2b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81241891e2b4, replyNumber=0, likeNumber=40, createdTime=2021-01-25, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81241891e2b4, moduleTitle=Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81241891e2b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985075, encodeId=1d1519850e511, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Cell Death Dis：缺氧诱导lncRNA PDIA3P1竞争性抑制miR-124-3p促进神经胶质瘤-EMS转化, objectType=article, longId=190242, objectId=8642190242f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8642190242f9, replyNumber=0, likeNumber=49, createdTime=2020-06-09, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8642190242f9, moduleTitle=Cell Death Dis：缺氧诱导lncRNA PDIA3P1竞争性抑制miR-124-3p促进神经胶质瘤-EMS转化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8642190242f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985081, encodeId=62bc1985081f6, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=JNNP：POEMS综合征早期VEGF检测可避免POEMS综合征的误诊和相关费用, objectType=article, longId=203279, objectId=f43f2032e947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f43f2032e947, replyNumber=0, likeNumber=43, createdTime=2021-08-06, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f43f2032e947, moduleTitle=JNNP：POEMS综合征早期VEGF检测可避免POEMS综合征的误诊和相关费用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f43f2032e947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985077, encodeId=390d19850e7a1, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Blood：免疫球蛋白可变结构域高通量测序揭示了POEMS综合征的特异性突变图谱, objectType=article, longId=191475, objectId=0efe1914e5de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0efe1914e5de, replyNumber=0, likeNumber=41, createdTime=2020-06-03, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0efe1914e5de, moduleTitle=Blood：免疫球蛋白可变结构域高通量测序揭示了POEMS综合征的特异性突变图谱, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0efe1914e5de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985079, encodeId=e8eb19850e949, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, objectType=article, longId=198566, objectId=a45b198566bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a45b198566bc, replyNumber=0, likeNumber=29, createdTime=2021-06-22, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a45b198566bc, moduleTitle=抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a45b198566bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985073, encodeId=5a2719850e398, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=ViiV Healthcare在美国提交了艾滋病毒新药fostemsavir的申请, objectType=article, longId=184388, objectId=272018438800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=272018438800, replyNumber=0, likeNumber=39, createdTime=2019-12-30, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=272018438800, moduleTitle=ViiV Healthcare在美国提交了艾滋病毒新药fostemsavir的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=272018438800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985078, encodeId=151719850e8b9, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, objectType=article, longId=193033, objectId=b12819303320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12819303320, replyNumber=0, likeNumber=33, createdTime=2020-11-23, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12819303320, moduleTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12819303320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985076, encodeId=777219850e6e8, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=NEJM：Fostemsavir治疗多药耐药性HIV感染者, objectType=article, longId=190923, objectId=36c31909232d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c31909232d, replyNumber=0, likeNumber=40, createdTime=2020-04-19, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c31909232d, moduleTitle=NEJM：Fostemsavir治疗多药耐药性HIV感染者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c31909232d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985072, encodeId=1a5019850e2ce, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, objectType=article, longId=183993, objectId=3c02183993a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c02183993a4, replyNumber=0, likeNumber=29, createdTime=2020-04-09, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c02183993a4, moduleTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c02183993a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985071, encodeId=a09d19850e13a, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=Neurology：日本POEMS综合征的患病率、临床特征和预后, objectType=article, longId=176667, objectId=93221e666742, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93221e666742, replyNumber=0, likeNumber=35, createdTime=2019-09-07, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93221e666742, moduleTitle=Neurology：日本POEMS综合征的患病率、临床特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93221e666742)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985070, encodeId=fde219850e006, content=<a href='/topic/show?id=23356e368c' target=_blank style='color:#2F92EE;'>#EMS#</a>, objectTitle=POEMS综合征的诊与治, objectType=article, longId=164782, objectId=3375164e8269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3375164e8269, replyNumber=0, likeNumber=45, createdTime=2020-01-03, rootId=0, userName=ms5768352621950538, userId=d2132500095, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3375164e8269, moduleTitle=POEMS综合征的诊与治, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3375164e8269)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMS

2020-05-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

远程血流动力学引导的心力衰竭管理对不同亚型肺动脉高压患者的影响：来自 MEMS-HF 研究的见解

2022-12-13

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

POEMS综合征：症状、病因、诊断与治疗

2023-07-10

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

GEMSTONE-301，舒格利单抗能否再次撼动不可切除III期肺癌治疗格局？

2022-09-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Lancet Neurol：无功无过——间充质干细胞与安慰剂治疗多发性硬化症(MESEMS)的安全性、耐受性和活性的研究

2022-04-05

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Molecular Systems Biology：AI助力抗击细胞因子风暴，可有效对抗新冠“夺命帮凶”

2023-01-16

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

NEJM:加拿大解除米非司酮REMS限制对流产安全的影响

2022-06-27

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2022-04-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

mSystems：人造甜味剂会促进全身炎症和脂肪肝的发展，不过有一种甜味剂例外…

2021-03-26

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效

2020-12-11

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Acacia Pharma针对术后恶心和呕吐的Barhemsy（静脉氨磺必利），喜获FDA批准上市

2021-01-25

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Cell Death Dis：缺氧诱导lncRNA PDIA3P1竞争性抑制miR-124-3p促进神经胶质瘤-EMS转化

2020-06-09

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

JNNP：POEMS综合征早期VEGF检测可避免POEMS综合征的误诊和相关费用

2021-08-06

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Blood：免疫球蛋白可变结构域高通量测序揭示了POEMS综合征的特异性突变图谱

2020-06-03

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

抗TNF-α单抗皮下制剂Remsima获批，治疗时间缩短至25分钟

2021-06-22

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

ViiV Healthcare在美国提交了艾滋病毒新药fostemsavir的申请

2019-12-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

2020-11-23

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

NEJM：Fostemsavir治疗多药耐药性HIV感染者

2020-04-19

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎

2020-04-09

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

Neurology：日本POEMS综合征的患病率、临床特征和预后

2019-09-07

ms5768352621950538 (审核中...)

前往app查看评论内容

#EMS#

POEMS综合征的诊与治

2020-01-03

科室
- - 订阅+
  - 更多科室
工具
服务